The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Colorectal, prostate, breast, testis cancers and malignant melanomas, gliomas and lymphomas showed moderate to strong cytoplasmic positivity. Remaining malignancies were weakly stained or negative.
A majority of malignancies showed moderate to strong cytoplasmic positivity. Skin cancer and several renal, cervical, lung stomach and liver cancers were weakly stained or negative.
Most malignant tissues displayed weak to moderate immunoreactivity. Malignant lymphomas, breast cancers and seminomas in testis showed cases of strong cytoplasmic immunoreactivity.
A few cases of breast cancer displayed strong cytoplasmic immunoreactivity. Most other tumors were moderately stained.
Validation
Two (or more) antibodies yielding partly similar staining patterns which are consistent with gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are consistent with gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are consistent with gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are consistent with gene/protein characterization data
